Cervical Cancer Cells HeLa Transfection Kit

Modes of administration

Reagent exhibits at least 90% transfection efficiency of siRNA delivery. Transfection efficiency was determined by qRT-PCR.

Description

Henrietta Lacks, an African-American woman, unwittingly contributed to some of the most significant medical breakthroughs in history when cervical cancer cells were taken from her body without her knowledge in 1951. These cells, known as the HeLa cell line, became one of the oldest and most widely used human cell lines in biomedical research, leading to discoveries in cell division, virology, drug discovery, and cancer biology. The HeLa cell line is immortal, meaning it can survive indefinitely in vitro and is highly proliferative due to an active telomerase during cell division, resulting in the prevention of aging and cell death. In addition to its properties as an excellent tool for cell division studies and drug effects, the HeLa cell line has a modal chromosome number of 82 and several copies of specific chromosomes. It also tests positive for keratin and lysophosphatidylcholine and contains human papillomavirus 18 sequences. The original HeLa cell line was established using cervical cancer cells taken from Henrietta Lacks, who later passed away from her cancer that same year. Since then, there have been many strains of HeLa cells, all descended from the original tumor cells. The HeLa transfection reagent kit is now available from CD BioSciences for the HeLa cervical cancer cell line, enabling specialized biomedical applications.